The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review

Wspolczesna Onkologia

Volumn 16, Issue 6, 2012, Pages 582-585

  Rolski, Janusz ^a   Karczmarek Borowska, Bozenna ^b   Śmietana, Anetta ^a  

^a Subcarpathian Oncology Centre in Rzeszów   (Poland)

^b UNIVERSITY OF RZESZÓW   (Poland)

Author keywords

Brain metastases; Breast cancer; Lapatinib

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; LAPATINIB; METHOTREXATE; NAVELBINE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CASE REPORT; CENTRAL NERVOUS SYSTEM METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HAND FOOT SYNDROME; HUMAN; INTRACRANIAL HYPERTENSION; KIDNEY TUMOR; LYMPH NODE METASTASIS; MAMMOGRAPHY; MULTIPLE CYCLE TREATMENT; NAUSEA; SIDE EFFECT;

EID: 84872533417     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.32494     Document Type: Article

References (27)

1. Gaul MD, Guo Y, Affleck K, et al. Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitor: G - thiazolylguinazolines. Bioorg Med Chem Lett 2003; 13: 637-40. (Pubitemid 36298457)
2. Reid A, Vidal L, Shaw H, de Bono J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (Her2/neu). Eur J Cancer 2007; 43: 481-9. (Pubitemid 46178540)
3. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinaze inhibitor GW572016. Oncogene 2004; 23: 646-53. (Pubitemid 38241266)
4. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22: 2865-72. (Pubitemid 41079905)
5. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-17. (Pubitemid 41103668)
6. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349-54. (Pubitemid 14205961)
7. Altaha R, Crowell E, Hobbs G, Higa G, Abraham J. Risk of brain metastases in HER2/neu positive breast cancer. J Clin Oncol 2004; 22: 22-47.
8. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-43. (Pubitemid 39141617)
9. Pestalozzi BC, Zahrieh D, Price KN, et al.; International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for Central Nerwous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-44. (Pubitemid 43778983)
10. Heinrich B, Brudler O, Siekiera W, et al. Development of brain metastases in metastatic breast cancer (MBC) responding to treatment with trastuzumab (abstract 147). Proc Am Soc Clin Oncol 2003; 22: 37.
11. Tham YL, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 2521-2.
12. Cameron D, Casey M, Press M, et al. A plase III randomized comparison of lapatynib and capecitabine versus capecitabine alone in woman with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res Treat 2008; 112: 533-43.
13. Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 47: 4190-8. (Pubitemid 46815065)
14. Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys 2002; 54: 810-7.
15. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 26: 1993-9.
16. Geyer CE, Forster J, Lindquist D, et al. Lapatynib plus capecytabine for HER2 - positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43. (Pubitemid 46021510)
17. Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatynib in patients with brain metastases from HER2 - positive breast cancer. Clin Cancer Res 2009; 15: 1452-9.
18. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Ann J Clin Oncol 2001; 24: 421-4. (Pubitemid 32730746)
19. Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in laptomeningeal metastases from breast cancer treated with capecytabine monotherapy: a case report. Clin. Breast Cancer 2006; 7: 164-6. (Pubitemid 44044015)
20. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007; 85: 223-7. (Pubitemid 47629405)
21. Hikino H, Yamada T, Johbara K, Obayashi N, Ozaki N. Potential role of chemoradiation with oral capecitabine in a breast cancer patient with central nerwous system relapse. Breast 2006; 15: 97-9. (Pubitemid 43210556)
22. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007; 25: 3853-8. (Pubitemid 47477260)
23. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107: 1348-54. (Pubitemid 44452785)
24. Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatynib plus capecytabine in subjects with brain metastases from HER2+ breast cancer envolled in the Lapatynib Expanded Access Program (LEAP) and French Authorisation Temporaive Utilisation. J Clin Oncol 2008; 26: 20 Suppl.
25. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2 - positive metastatic breast cancer with lapatynib and capecitabine in the lapatynib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer 2010; 102: 995-1002.
26. Bachelot TD, Romieu G, Campone M, et al. LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecytabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 2011; 29: Suppl. [Abstract 509].
27. Zhou H, Kim YS, Peletier A, McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004; 58: 344-52. (Pubitemid 38142458)